

## MIT Open Access Articles

*High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome*

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

**Citation:** Münch, Natasha Stephens et al. "High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome." *Gastroenterology*, 157, 2 (August 2019): 492–506.e2 © 2019 The Author[s]

**As Published:** 10.1053/J.GASTRO.2019.04.013

**Publisher:** Elsevier BV

**Persistent URL:** <https://hdl.handle.net/1721.1/126794>

**Version:** Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

**Terms of use:** Creative Commons Attribution-NonCommercial-NoDerivs License





Published in final edited form as:

*Gastroenterology*. 2019 August ; 157(2): 492–506.e2. doi:10.1053/j.gastro.2019.04.013.

## High-fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via IL8 and Alterations to the Gut Microbiome

Natasha Stephens Münch<sup>1,2,#</sup>, Hsin-Yu Fang<sup>1,#</sup>, Jonas Ingermann<sup>1,2,#</sup>, H. Carlo Maurer<sup>1,3</sup>, Akanksha Anand<sup>1</sup>, Victoria Kellner<sup>1</sup>, Vincenz Sahm<sup>1</sup>, Maria Wiethaler<sup>1</sup>, Theresa Baumeister<sup>1</sup>, Frederik Wein<sup>1</sup>, Henrik Einwächter<sup>1</sup>, Florian Bolze<sup>2,4,5</sup>, Martin Klingenspor<sup>2,4,5</sup>, Dirk Haller<sup>6</sup>, Maria Kavanagh<sup>7</sup>, Joanne Lysaght<sup>7</sup>, Richard Friedman<sup>3</sup>, Andrew J. Dannenberg<sup>8</sup>, Michael Pollak<sup>9</sup>, Peter R Holt<sup>10</sup>, Sureshkumar Muthupalani<sup>11</sup>, James G. Fox<sup>11</sup>, Mark T. Whary<sup>11</sup>, Yoomi Lee<sup>3</sup>, Tony Y. Ren<sup>3</sup>, Rachael Elliot<sup>12</sup>, Rebecca Fitzgerald<sup>13</sup>, Katja Steiger<sup>14</sup>, Roland M. Schmid<sup>1</sup>, Timothy C. Wang<sup>3</sup>, Michael Quante<sup>1,\*</sup>

<sup>1</sup>Department of Internal Medicine, Technical University of Munich, Germany <sup>2</sup>Chair of Molecular Nutritional Medicine, Technical University of Munich, Germany <sup>3</sup>Irvine Cancer Research Center, Columbia University, New York, USA <sup>4</sup>EKFZ – Else Kröner-Fresenius Center for Nutritional Medicine, Technical University of Munich, Germany <sup>5</sup>ZIEL – Institute of Food & Health, Technical University of Munich, Germany <sup>6</sup>Chair of Nutrition and Immunology; Technical University of Munich, Germany <sup>7</sup>Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin, Ireland <sup>8</sup>Weill Cornell Medical College, New York, NY, USA <sup>9</sup>McGill University, Montreal, Quebec, Canada <sup>10</sup>Rockefeller University, New York, NY, USA <sup>11</sup>Massachusetts Institute of Technology, Cambridge, MA, USA <sup>12</sup>University of California San Francisco, CA, USA <sup>13</sup>Cambridge University, Cambridge, UK <sup>14</sup>Institute of Pathology, Technical University of Munich, Germany

### Abstract

\*Correspondence: michael.quante@tum.de (M.Q.).

#authors contributed equally

Author contributions:

NSM, HYF, JI performed experiments, analyzed data and wrote the manuscript, MK, MK, JL, YL, FW, HCM, VK, VS, MW, TB, AA, FB, JL, MTW, MK and DH performed experiments and analyzed data

RF, HE performed bioinformatics

PRH, AJD performed human serum study, analyzed data and edited manuscript

MP quantified analytes in human serum

SM, JGF performed germfree experiments and analyzed data

RE, RF performed human microbiome experiments and analyzed data

KS performed histopathological evaluation

RMS analyzed data and provided funding

TCW analyzed data, wrote the manuscript, provided funding

MQ designed and supervised the study, analyzed data, wrote the manuscript, provided funding

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of interests: none

Gene Expression Analysis:

Raw data have been deposited in National Center for Biotechnology Information's Gene Expression Omnibus (GEO) (GSE103616)

**Background & Aims:** Barrett's esophagus (BE) is a precursor to esophageal adenocarcinoma (EAC). Progression from BE to cancer is associated with obesity, possibly due to increased abdominal pressure and gastroesophageal reflux disease, although this pathogenic mechanism has not been proven. We investigated whether environmental or dietary factors associated with obesity contribute to progression of BE to EAC in mice.

**Methods:** Tg(ED-L2-IL1RN/IL1B)#Tcw mice (a model of BE, called L2-IL1B mice) were fed a chow (control) or high-fat diet (HFD), or crossbred with mice that express human IL8 (L2-IL1B/IL8 mice). Esophageal tissues were collected and analyzed for gene expression profiles and by quantitative PCR, immunohistochemistry, and flow cytometry. Organoids were established from BE tissue of mice and cultured with serum from lean or obese individuals, or neutrophils from L2-IL1B mice. Feces from mice were analyzed by 16s rRNA sequencing and compared to 16s sequencing data from patients with dysplasia or BE. L2-IL1B were mice raised in germ-free conditions.

**Results:** L2-IL1B mice fed a HFD developed esophageal dysplasia and tumors more rapidly than mice fed the control diet; the speed of tumor development was independent of body weight. The acceleration of dysplasia by the HFD in the L2-IL1B mice was associated with a shift in the gut microbiota and an increased ratio of neutrophils to natural killer cells in esophageal tissues, compared to mice fed a control diet. We observed similar differences in the microbiomes from patients with BE that progressed to EAC vs patients with BE that did not develop cancer. Tissues from dysplasias of L2-IL1B mice fed the HFD contained increased levels of cytokines that are produced in response to CXCL1 (the functional mouse homolog of IL8, also called KC). Serum from obese patients caused organoids from L2-IL1B/IL8 mice to produce IL8. BE tissues from L2-IL1B mice fed the HFD and from L2-IL1B/IL8 mice contained increased numbers of myeloid cells and cells expressing *Cxcr2* and *Lgr5* mRNAs (epithelial progenitors) compared to mice fed control diets. BE tissues from L2-IL1B mice raised in germ-free housing had fewer progenitor cells and developed less dysplasia than in L2-IL1B mice raised under standard conditions; exposure of fecal microbiota from L2-IL1B mice on HFD to L2-IL1B mice on control diet accelerated tumor development.

**Conclusions:** In a mouse model of BE, we found that a HFD promoted dysplasia by altering the esophageal microenvironment and gut microbiome, thereby inducing inflammation and stem cell expansion, independent of obesity.

## Lay Summary:

In an inflammation induced mouse model of esophageal tumor development a diet rich in fat is leading to accelerated tumor growth in part caused by changes in the gut microbiome which induces an accelerated inflammatory microenvironment.

## Keywords

NK cells; neutrophils; cytokines; IL1B

## Introduction

BE is thought to arise as a consequence of gastro-esophageal reflux disease (GERD), which damages the esophageal mucosa, leading to a replacement of squamous epithelium by a metaplastic columnar epithelium above the gastroesophageal junction (GEJ)<sup>1</sup>. The increase in EAC incidence in the Western world has led to some uncertainty in the clinical management of BE and the estimation of its risk for EAC. While current strategies employ aggressive screening, surveillance and/or ablation procedures, the benefits of such procedures have been difficult to demonstrate<sup>2</sup> and a better understanding of risk factors is needed.

In addition to male gender, age and tobacco use<sup>3</sup>, obesity is strongly associated with the development of EAC<sup>4</sup> and is now endemic in Western countries and Asia. Obesity or a high waist circumference are thought to promote BE/EAC through increased abdominal pressure and GERD<sup>5</sup>, although this mechanism has not been proven and the degree of GERD correlates poorly with disease progression. Evidence linking obesity to cancer risk derives primarily from observational cohort studies, which may not establish directly causality, but identified associations of multiple obesity-related factors (hormones, cytokines, adipokines) with increased risk and poor outcome. In this context, obesity is mostly used as a proxy for an underlying but still undefined mechanism<sup>6</sup>. This leaves the possibility that environmental or dietary factors that are prevalent in obese patients influence the risk of BE progression, rather than increased body fat per se<sup>7</sup>, as recently demonstrated for colorectal cancer<sup>8</sup>. Changes in diet can lead to alterations in the gut microbiome<sup>9</sup>, with effects on stem cell biology<sup>10</sup> and thus the susceptibility to gastrointestinal neoplasia. Furthermore, a Western-style diet itself can contribute to chronic inflammation<sup>8, 11, 12</sup>, which itself can favor the emergence of gut microbiota that favor carcinogenesis<sup>13</sup>.

Here, we utilize the L2-IL1B mouse model of BE<sup>14</sup> to analyze dietary effects of a HFD on BE progression. The L2-IL1B mouse model expresses human interleukin 1 $\beta$  in the esophagus and forestomach squamous epithelium, resulting in inflammation with progression to metaplasia and dysplasia. We demonstrate that HFD leads to global changes in the gut microbiome that mirror closely those observed in BE patients, and facilitates the establishment of an inflammatory pro-carcinogenic microenvironment at the GEJ accelerating disease progression.

## Important Methods

### Animals

The mouse model (L2-IL1B, Tg(ED-L2-IL1RN/IL1B)#tcw)<sup>14</sup>, was backcrossed to C57BL/6J mice and fed a standard Chow diet from birth until weaning, and water *ad libitum*. Between 6 and 8 weeks of age, mice were started on HFD, control diet or remained on the Chow (ssniff). For bedding transfer experiments, cages were filled half with fresh bedding, while the other half was bedding from HFD cages starting at the age of 6 weeks until 9 months. IL8 mice<sup>15</sup> and Mc4rX16 mice<sup>16</sup> were bred with L2-IL1B, mice to obtain L2-IL1B/IL8Tg mice and L2-IL1B/Mc4R mice. Germfree mice were generated by embryo transfer rederivation of conventional L2-IL1B mice into germfree Swiss recipient mothers<sup>17</sup>

and maintained in sterile isolators on autoclaved food (RMH3000, Purina, USA) comparable to the standard chow and water (Suppl. Figure 8). Sterility was confirmed every other week by 16s PCR, aerobic, anaerobic and fungal culture as well as Gram stains of fecal smears. Animal experiments were approved by the District Government of Bavaria and performed in accordance with the German Animal Welfare and Ethical Guidelines and by the Committee on Animal Care at the MIT, USA.

### Tissue preparation and disease evaluation

Macroscopic scoring of the squamocolumnar junction (SCJ) and the esophagus was performed and scores averaged as shown in Suppl. Fig. 1B, C. For further RNA or protein analysis the SCJ was macroscopically identified as the first 2 mm of columnar tissue and cut with a magnifying glass dissection-scope to eliminate squamous tissue contamination as good as possible. Mouse tissues were fixed in formalin and paraffin-embedded then cut and stained with H&E (Haematoxylin and eosin). Histopathological scores were performed by an experienced mouse pathologist by previously established criteria for the influx of immune cells per high-power field, metaplasia and dysplasia<sup>14</sup> (Suppl. Fig 1D): Inflammation was scored by the percentage of different immune cells (mostly neutrophilic myeloid cells) in a defined tissue area of the SCJ in a high-power field evaluation. Metaplasia was evaluated by the abundance of mucus producing or cells per gland and the abundance of glands with mucus producing cells in the BE area at the SCJ. Dysplasia was evaluated by the amount of cellular atypia and the presence of low or high grade dysplasia in single or multiple glands as assessed by experienced mouse pathologists. Mucus production was assessed by Periodic Acid-Schiff- (PAS) staining and quantified as percentage of PAS positive area in BE regions. Crypt fission was quantified by counting fused crypts in the BE region.

### Statistics

Statistical analysis was performed using Graph Prism 6 with Student's t-tests or one-way or two-way ANOVA's with p-values noted in each corresponding figure. For 2-way ANOVA, Sidak-Holm post-hoc was used, for 1 way ANOVA, Tukey post-hoc was used.

## Results

### HFD accelerates esophageal dysplasia in the L2-IL1B mouse model, independent of obesity

To study the effect of diet on BE and EAC, we fed wild type (WT) and L2-IL1B mice either Chow or high fat diet (HFD, 48% fat, Suppl. Fig. 1A). No pathological phenotype at the squamocolumnar junction (SCJ) in Chow and HFD fed WT mice (Fig. 1A–F, Suppl. Fig. 1B, C, D), in contrast to L2-IL1B mice on both diets. Compared to Chow fed L2-IL1B mice, a significant increase in macroscopic tumor burden at the SCJ and in the esophagus was observed in L2-IL1B mice on HFD at 9 and 12 months (Fig. 1A, B). Both L2-IL1B mice on HFD and Chow diet developed increasing but similar amounts of inflammation and columnar metaplasia over time (Fig. 1A, C, D, F). However, HFD-treated L2-IL1B mice exhibited a significant increase in proliferation only at the age of 12 months (Fig. 1A,G) compared to chow fed L2-IL1B mice. This correlated with markedly elevated dysplasia

scores in HFD fed L2-IL1B mice as early as 9 months (Fig. 1A, E), demonstrating an accelerating effect of HFD on esophageal carcinogenesis in the mouse model.

In contrast to HFD-induced obesity in WT mice (48% weight gain ( $p < 0.001$ )), HFD-fed L2-IL1B mice did not gain body weight ( $p < 0.001$ ) (Fig. 1H). Both fat and lean mass were lower in L2-IL1B mice on HFD relative to WT mice on HFD (Suppl. Fig. 1E). Thus, acceleration of the BE phenotype occurred independent of body weight (Fig. 1I). To examine whether obesity alone without an additional inflammatory component was sufficient to influence BE progression, we interbred the L2-IL1B mice with mice lacking a functional melanocortin-receptor-4 ( $Mc4r^{W16X}$ )<sup>16</sup>, which exhibit an obese phenotype comparable to HFD-induced obesity and are modeling the most common monogenic cause for obesity in humans<sup>18</sup> (Suppl. Fig. 2A–C). L2-IL1B mice with a heterozygous ( $Mc4r^{+/-}$  or  $Mc4r^{het}$ ) or homozygous ( $Mc4r^{-/-}$  or  $Mc4r^{ki}$ ) loss of  $Mc4r$  showed a similar BE phenotype as L2-IL1B mice on a chow diet. In contrast to L2-IL1B mice on a HFD,  $Mc4r^{het}$ ; L2-IL1B mice showed an absence of disease acceleration, with no increase in the level of inflammation, metaplasia or dysplasia (Suppl. Fig. 2A,D–G). There was no increase in the expression of inflammatory cytokine (data not shown), splenomegaly (Suppl. Fig. 2H) in L2-IL1B/ $Mc4r^{het}$  and L2-IL1B/ $Mc4r^{ki}$  mice, compared to L2-IL1B mice (Suppl. Fig. 2I)<sup>14</sup>. These data suggest that genetic obesity does not promote BE progression, and HFD accelerates the phenotype independent of body weight.

### HFD induces an immune response leading to a distinct local inflammatory reaction

Previously, we showed that overexpression of IL1B in the esophagus leads to upregulation of pro-inflammatory cytokines<sup>14</sup>. HFD promotes chronic inflammatory responses, as has been demonstrated for colorectal carcinogenesis<sup>8</sup>. Thus, we postulated that the enhancement of dysplasia in L2-IL1B mice by HFD might be due primarily to a change of systemic and esophageal inflammation profiles. Although our tissue inflammation metric was not significantly altered in HFD L2 mice compared with chow fed L2 mice (Fig. 1C), Gene-expression (Fig. 2A) and Gene-Set-Enrichment-Analysis (GSEA) (Suppl. Fig. 3A) of SCJ tissue revealed changes in cytokine expression associated with HFD. Key mediators of this cytokine response were related to cell survival, proliferation, angiogenesis, apoptosis and importantly chemoattraction for the observed immune cells (Fig. 2A, B and Suppl. Fig. 3B).  $\alpha$ SMA<sup>+</sup> myofibroblasts within the SJC region were significantly increased in HFD fed L2-IL1B mice (Fig. 2E), indicating an activated stromal reaction associated with the inflammatory response. Serum from L2-IL1B mice fed with HFD significantly stimulated the growth of 3D mouse BE organoids (Fig. 2C), compared to serum from Chow mice, suggesting that systemic inflammatory components affect epithelial cell growth. Of note, serum analysis of 20 obese versus non-obese patients revealed that the pro-inflammatory cytokines IL-6 and leptin were elevated, and adiponectin decreased (Suppl. Fig. 4A). Additionally, we observed an upregulation of chemokines involved in recruitment and/or differentiation of myeloid cells and T cells, such as CCL6, CCL12 and G-CSF, (Fig. 2B, Suppl. Fig. 3B) in esophageal tissue in L2-IL1B mice on HFD. Importantly, the functional mouse homolog of IL8, KC or CXCL1, was among those cytokines in the chemokine array (Fig 2B), and was also upregulated 6-fold in esophagus tissue lysates from L2-IL1B mice on HFD for 12 months (Fig. 2D). Thus, HFD activates a systemic immune response that also



affects the local microenvironment. Cytokine arrays of SCJ and esophageal tissue in Chow and HFD fed WT mice did not show any major changes; nevertheless, serum from WT-HFD showed a mainly obesity related phenotype, compared to chow fed WT mice, whereas HFD fed L2-IL1B mice showed an accelerated inflammatory phenotype compared to Chow fed L2-IL1B mice (Suppl. Fig.3C).

### HFD leads to levels of IL8/KC chemokines that promote esophageal dysplasia

Esophageal tissue IL8 expression has been shown to be associated with histopathological inflammation in 50 BE patients and has been hypothesized to play a role in esophageal carcinogenesis<sup>19</sup>. Consistent with these earlier clinical observations, levels of the functional mouse IL8 homologue, KC or CXCL1<sup>20</sup>, were significantly increased in the esophagus of HFD fed L2-IL1B mice (Fig. 2B, D). We also noted increased IL8 levels in conditioned media of a human EAC compared to BE or squamous cell lines (Fig. 2 F), and increased IL8 levels in conditioned media from BE and EAC esophageal biopsies compared to normal and esophagitis (Fig. 2G). Since rodents lack the IL8 gene, we crossed a human IL8-BAC-transgenic mouse model<sup>15</sup>, which exhibits tissue specific, physiologic IL8 gene regulation, with the L2-IL1B mice to generate L2-IL1B/IL8Tg mice. L2-IL1B/IL8Tg mice showed an accelerated phenotype, remarkably similar to that of L2-IL1B HFD mice (Fig. 3A–C, Suppl. Fig 4B), with a 2-fold increase in dysplasia scores (Fig. 3D), along with increased proliferation (Fig. 3E) and differentiation (Fig. 3F). Furthermore, we observed significant increases in aSMA<sup>+</sup> stromal myofibroblasts (Fig. 3G).

Utilizing gene expression data from L2-IL1B/IL8Tg compared to L2-IL1B mice, we generated an IL8 specific gene set including 150 upregulated and 110 downregulated genes. Genes stimulated by IL8 pathway activity were enriched in HFD fed WT and L2-IL1B mice compared to Chow fed mice (Fig. 3H), suggesting that the IL8/CXCL1 chemokine family contributes to the observed HFD L2-IL1B phenotype. However, we could not detect a difference in serum IL8 levels (Suppl.Fig. 4C) nor a correlation with obesity (Suppl. Fig. 4D) in patients with BE, LGD, HGD or EAC. Instead, elevated tissue concentrations of IL8 measured in conditioned medium from human patient biopsies (Fig. 2G), suggested that IL8 acts at a local level. When we treated BE organoids from L2-IL1B/IL8Tg mice with lean or obese human sera, obese sera stimulated growth of BE organoids (Suppl. Fig.4E). Relative to lean serum treatment, obese serum resulted in higher levels of L2-IL1B/IL8Tg mouse epithelial cell derived IL8 in the supernatant (Fig. 3I), indicating that serum components from obese subjects could induce local epithelial IL8 secretion. These data demonstrate that IL8 secretion in esophageal tissue is induced by HFD and plays an important role in stimulating BE cell proliferation *in vitro* and *in vivo*.

### HFD increases neutrophils and decreases NK cells at the SCJ

Assessment of the immune cell infiltrate in the lower esophagus using FACS (Suppl.Fig. 5A) in 12-month old L2-IL1B HFD mice with dysplasia showed a significant increase in neutrophils and immature myeloid cells (IMC) (Fig. 4A), previously linked to the IL8 pathway<sup>15</sup>. No differences in macrophages, CD4 helper T-cells, CD8 cytotoxic T-cells or gamma-delta T-cells were observed (Suppl. Fig. 5B). The influx of granulocytic myeloid cells was confirmed by IHC of the SCJ and lower esophagus (Fig. 4B) and was not observed

in the glandular stomach (data not shown), highlighting the specificity of the response for the SCJ. Additionally, we observed a significant decrease in NK cells in HFD compared to chow fed mice (Fig. 4A), suggesting an inhibitory effect by neutrophils on NK cells, as previously reported<sup>21</sup>. We also found increased neutrophils in esophageal tissue of L2-IL1B/IL8Tg mice (Fig. 4C, D), consistent with the known role of IL8 as a recruiter of granulocytic immune cells<sup>15</sup>, while no difference could be detected for other immune cells (Suppl. Fig. 6A, B). Importantly, a significant increase of immune cells expressing IL8 receptor CXCR2 was observed in L2-IL1B HFD and L2-IL1B/IL8-Tg mice compared to L2-IL1B mice (Fig. 4E,F).

Co-cultured mouse BE organoids with neutrophils from the spleens of 9–12 months old L2-IL1B mice demonstrated a significant increase in proliferation and organoid growth in a dose-dependent fashion suggesting a direct stimulatory effect of neutrophils on BE epithelial cells (Fig. 4G). This response was mediated by inflammatory cytokines, such as leptin and IL-10, which were secreted solely under organoid-neutrophil co-culture conditions (Fig. 4H,I).

### The esophageal inflammatory niche recruits SCJ progenitor cells

In addition to elevated CXCR2<sup>+</sup> immune cells, we observed increased CXCR2 expressing epithelial cells in BE regions during disease progression (Fig. 5A), suggesting an effect of the inflammatory microenvironment on a distinct epithelial cell population. Previous studies by our group<sup>14</sup> and others<sup>22</sup> have pointed to the gastric SCJ<sup>23</sup> as the origin of BE and EAC, with expansion of SCJ progenitor cells into the esophagus in response to chronic inflammation, thus giving rise to metaplastic and dysplastic lesions<sup>1</sup>. Indeed, when we analyzed gene expression changes related to HFD and IL8 expression, we observed a highly significant enrichment of stem cell signatures (Fig. 5B,C). In situ hybridization revealed a significant increase of the naturally present Lgr5<sup>+</sup> progenitor cells<sup>24</sup> in areas of BE at the SCJ in L2-IL1B mice on HFD, compared to Chow, and in L2-IL1B/IL8Tg mice (Fig. 5D). Lgr5<sup>+</sup> cells could be found in the typical location at the bottom of the first SCJ crypt as well as in the BE region at the SCJ. These findings suggest that IL8/KC family members may directly stimulate through CXCR2 the expansion of Lgr5 progenitor cells at the SCJ. Indeed, Lgr5<sup>+</sup> cells in HFD fed L2-IL1B mice highly expressed the IL8 receptor, CXCR2, and Lgr5<sup>+</sup> cells increased with dysplastic progression (Fig. 5E). Additionally, analysis of BE specimens from 12-month old L2-IL1B HFD and L2-IL1B/IL8Tg mice showed significantly more crypt fission compared to age-matched L2-IL1B chow fed mice (Fig. 5F). These observations suggest a mechanism by which activation of SCJ progenitor cells by HFD/IL8 through CXCR2 could lead to crypt fission and expansion of SCJ glands into the esophagus, thus giving rise to metaplasia and dysplasia.

### HFD altered intestinal microbiota promote the accelerated immune response and dysplasia phenotype

Diet affects the composition of gut microbiota<sup>9</sup> and dysbiosis is linked to cancer development<sup>13</sup>. Previously, a modest reduction in microbial diversity in BE tissue in the human esophagus was shown<sup>25</sup>, matching our results from 16S-rRNA gene sequencing of bacterial DNA isolated from the mouse SCJ. No clustering could be observed in the tissue



from WT or L2-IL1B mice (Suppl. Fig. 7A) suggesting that esophageal microbes are difficult to categorize in their role during carcinogenesis.

Since the lower GI tract harbors the majority of the intestinal microbiota, which mediate much of the dietary effects, we analyzed the intestinal microbiota by 16S-rRNA gene sequencing of fecal samples from 6-month-old WT and L2-IL1B mice on Chow, HFD, or nutrient-matched experimental diet<sup>26</sup> (referred to as 'Control', Suppl. Fig. 8A). There was no difference in the SJC histopathology between Control and Chow, indicating that HFD, rather than the purified nutrient component, was responsible for the accelerated phenotype (Fig. 6F, Suppl. Fig. 8B–E). Analysis of microbial  $\beta$ -diversity showed separate clustering of HFD fed L2-IL1B mice compared to all other groups, with a unique taxonomic profile, while WT and L2-IL1B harbored very distinct microbiota on control and on chow (Fig. 6A). Importantly, we observed an altered *Firmicutes* to *Bacteroidetes* ratio in HFD fed mice (Fig. 6B, Suppl. Fig. 7B,C), which correlated well with the increased *Firmicutes*: *Bacteroidetes* ratio in previously published patient (BE and HGD) data<sup>25</sup> (Fig. 6B), although these data were from different tissue sites (feces versus esophagus) and comparisons of the microbiota between two species must be made cautiously.

To investigate whether the gut microbiota in general influenced inflammation and tumor development in the L2-IL1B HFD mouse model, we re-derived L2-IL1B mice as germfree (GF) and found a marked reduction of inflammation, metaplasia and dysplasia, with an increase in goblet-like cells (Fig. 6C, D, Suppl. Fig. 6C). This correlated with a significantly reduced influx of neutrophils and IMCs into the esophagus of germfree L2-IL1B mice (Fig. 6E), directly linking the elimination of enteric microbes to the inflammatory phenotype. Lgr5+ and Cxcr2+ cells at the SJC were significantly decreased under germfree conditions (Fig. 5A,D). When transferring bedding including feces from L2-IL1B mice on HFD to cages of L2-IL1B mice on Control diet over 9 months, the tumor phenotype could be transmitted, suggesting that the fecal microbial community is at least partly responsible for the SCJ phenotype (Fig. 6F and Suppl. Fig. 8F). Changes in the microbial community structure from HFD fed L2-IL1B mice pointed to unique functions, as the well-established PICRUSt pipeline<sup>27</sup> *in silico* analysis of 16S-rRNA genes generated a predictive metagenome in KEGG pathway analysis. Clustering KEGG data showed that in L2-IL1B mice, HFD differentiated microbial function from Chow and Control diet (Fig. 6G). Functional pathway differences between HFD and Control in L2-IL1B mice<sup>27</sup> (Fig. 6H, Suppl. Fig. 7D) suggest a microbial HFD associated component contributing to disease acceleration. One of the mostly regulated pathways in KEGG analysis in HFD fed L2-IL1B mice was bacterial Lipopolysaccharides (LPS) biosynthesis (Fig. 6I), known to have effects on inflammatory responses. GSEAs revealed an upregulation of the inflammatory response to LPS and Toll-Like Receptor (TLR) signaling in the SCJ of L2-IL1B HFD mice, suggesting that such gut microbiota changes are likely influenced through TLR signaling (Fig. 6J, K and Suppl. Fig. 7E).

## Discussion

The increase in BE and EAC in developed countries points to pathogenetic environmental influences. However, the increase in obesity<sup>32–35</sup> did not precede this rise in EAC as one

might suspect for a causative factor<sup>28</sup>. We provide evidence for an alternative hypothesis, suggesting that obesity and BE/EAC are secondary to the increasing consumption of a western-style or HFD<sup>7</sup>. HFD accelerated BE progression in the L2-IL1B mouse model through effects on gut microbiota, demonstrating the importance of the microbiome, and linking its influence in part to activity of the IL8/CXCL1 chemokine family within a distant altered inflammatory microenvironment.

HFD induced obesity in WT mice but not in L2-IL1B mice, where it accelerated the BE/EAC phenotype. The absence of weight gain in L2-IL1B mice on HFD was likely due to systemic effects of IL1B, but also raises the question as to whether increased body fat alone contributes to BE/EAC. In contrast to the HFD model, a genetic model of obesity (Mc4r<sup>x16</sup>) did not increase BE progression, arguing against body weight alone as a driver of esophageal carcinogenesis in mice. Instead, disease acceleration correlated with increased inflammation<sup>29</sup>, through pro-inflammatory cytokines and chemokines<sup>30</sup> altering the local microenvironment with accumulation of immune cells and  $\alpha$ SMA+ fibroblasts, which are known to recruit immune cells through specific factors (VEGF, HGF, MMP2, and IL8)<sup>31</sup>.

In our initial report of L2-IL1B mice, we noted upregulation of IL-6, a downstream target of IL1B, whose genetic ablation could attenuate the phenotype<sup>14</sup>. Here, we demonstrate a role for HFD in BE progression through inflammatory factors such as the IL8/CXCL1 family of chemokines<sup>14</sup>. The IL8/CXCL1 chemokine family is an additional well-defined downstream target of IL1B, and we observed elevated levels of the functional murine homolog CXCL1 at the SCJ of HFD treated L2-IL1B mice. Other studies have also suggested that chemokines such as IL-8 and IL1B are involved in esophageal carcinogenesis, and that CXCR1 and CXCR2 are expressed in esophageal mucosa<sup>32</sup>. During disease progression, human BE tissue produces abundant IL8, which is strongly overexpressed in EAC patients, pointing to an important role in human carcinogenesis<sup>19</sup>. Together with the observed elevation of CXCL1 gene and protein levels, and most importantly, the finding that immature myeloid cells and neutrophils were mainly attracted to the SCJ, this led us to further examine the effect of IL8 pathway in our mouse model. Indeed, reconstitution of the human IL8 gene in the BE mouse model resulted in acceleration of dysplasia, mimicking the HFD phenotype, confirming the importance of local IL-8 expression.<sup>33</sup> In this study, we were not able to investigate comprehensively other inflammatory mediators, whether expressed locally or systemically. It has previously been demonstrated that circulating cytokines, including IL8, are associated with increased risk for BE<sup>34</sup> and could be used as potential biomarker<sup>35</sup>. Nevertheless, IL8 likely plays a key local role during esophageal carcinogenesis<sup>19</sup>, with the IL8 specific gene signature being enriched in GSEA analysis of HFD fed L2-IL1B mice. IL8 is known to be upregulated by pro-inflammatory cytokines or pathogen-associated factors through toll-like receptors (TLRs)<sup>36</sup>, likely through an alteration of the gut microbiome. Although we cannot prove directly in our work that a specific microbial species is activating IL8 signaling in the esophagus, we provide evidence in our KEGG analysis: The bacterial community profile associated with LPS biosynthesis, known to activate TLR signaling, was upregulated in the SCJ of L2-IL1B HFD mice. We would therefore speculate, that gut microbiota changes on the immune system are influenced through TLR signaling, which in turn has an effect on IL8 activation, which is known to activate granulocytic myeloid cells that appear essential to the BE phenotype.

IL8 is a chemoattractant for myeloid cells through its cell surface receptors, CXCR1 and CXCR2<sup>15</sup>. In HFD fed L2-IL1B and L2-IL1B/IL8Tg mice, we observed an accumulation of CXCR2+ IMCs and neutrophils. In combination with organoid culture data, these findings suggest that dietary fat components can result in increased local secretion of IL8/CXCL1 chemokines that then promote the accumulation of immature, granulocytic cells in the esophagus. These observations are consistent with previous studies that reported an increase in IMCs resulting from HFD feeding of WT mice<sup>37</sup>, and *H. felis* infection of WT mice<sup>11</sup>. Of note, bile acid treated L2-IL1B mice also exhibit a granulocytic shift, along with acceleration of dysplasia at the SCJ region<sup>14</sup> pointing to the importance of neutrophils.

IMCs can carry out both, tumor promoting and immunosuppressive functions<sup>38</sup>. A subtype comprising CD11b+Ly6G<sup>high</sup>Ly6C<sup>low</sup> neutrophils and CD11b+Ly6G<sup>low</sup>Ly6C<sup>high</sup> IMCs likely contributes to epithelial growth and progression, as demonstrated in 3D organoid cultures. However, myeloid cells may also possess immunosuppressive properties that could modulate tumor immunity. Tumor-derived *G-CSF* can promote the differentiation of IMCs into immunosuppressive neutrophils<sup>39</sup> that inhibit cytotoxic T-cell responses, thereby facilitating tumor growth and metastasis<sup>40</sup>. Upregulation of G-CSF in HFD fed L2-IL1B mice underlines this possibility of increased myeloid suppressor cell recruitment and/or differentiation into an immunosuppressive local phenotype. While there was no significant change in cytotoxic T-cell numbers, increases in neutrophils were accompanied by reduced NK cells. Indeed, neutrophils protect against NK cell mediated clearance of tumor cells<sup>21</sup> and have been proposed as a positive prognostic markers in esophageal cancer<sup>41</sup>. Although there are clearly limitations to studies of inflammation in a pro-inflammatory mouse model of BE, the findings suggest that an altered neutrophils to NK ratio may portend a poor prognosis, as shown in other cancers<sup>42</sup>.

Apart from IL8 effects on the esophageal inflammatory niche, we observed an epithelial effect of the IL8/CXCL1 chemokine family, with an expansion in the gastric SCJ of Cxcr2 expressing Lgr5+ progenitor cells with accelerated dysplasia. The increase in crypt fission at the SCJ is likely related to this expanded stem/progenitor cell pool. Thus, the transition of the normal SCJ niche to a distinct IL8 driven inflammatory niche may enhance the expansion of BE lesions into the esophagus, a scenario similar to that recently described in skin lesions<sup>43</sup>, providing a mechanism for HFD to influence tissue regeneration and cancer incidence<sup>44, 45</sup>.

The gut microbiome is modulated by diet<sup>46</sup>, and growing evidence indicates that both the microbiome<sup>9</sup> and dietary components<sup>8</sup> can potentiate cancer risk as shown for intestinal cancer<sup>13</sup>. However, such an interaction has not yet been reported for esophageal carcinogenesis. Esophageal carcinogenesis was attenuated under germfree conditions, with reduced influx of immune cells and decreased expansion of stem and epithelial cells. As suggested by previous studies<sup>47,48</sup> and in line with reduced Cxcr2 expressing cells in germfree mice, epithelial IL8 secretion was likely induced by the gut microbiota. We propose that alterations in the esophageal immune niche might be related to body wide inflammatory effects of an altered gut microbiome as reported already for metabolic diseases<sup>49</sup>, and as such play a key role in esophageal carcinogenesis. The findings may be relevant to the care and treatment of patients with BE, as dietary modifications could change

the gut microbial community and delay or prevent BE progression. Moreover, one could speculate that elimination of specific microbial species through antibiotics might provide a potential tool for cancer prevention. Nevertheless, such commensal bacteria have yet to be identified and further studies are needed to elucidate the role of the gut and/or esophageal microbiome in predicting the development of BE<sup>50</sup>. While GERD and bile acid reflux are known to induce inflammation in the esophagus and believed to contribute to the development of early BE, the gut microbiome may play an important role in malignant progression through acceleration of the inflammatory microenvironment.

While there are alterations in the composition of the microbial community in EAC, there were only modest reductions in microbial diversity in human BE samples<sup>25</sup>. In accordance, we found only modest changes in the microbiota at the SCJ in L2-IL1B mice, while microbial composition in the colon was changed upon feeding HFD, with an altered Firmicutes:Bacteroidetes ratio that correlated with BE progression. This ratio, together with a lower microbial  $\alpha$ -diversity, have been associated with HFD<sup>46</sup> and mirrored the changes seen in BE patients. Although the fecal material may not fully reflect the changes in the microbiota colonizing the gastroesophageal region, we would suggest that the fecal microbiota is highly relevant, and may have a systemic impact on BE progression. Changes in gut microbiota may account for the inflammatory phenotype observed in HFD L2-IL1B mice and importantly, can induce an increased cancer phenotype, if transferred to L2-IL1B mice on chow diet. 16S-rRNA gene profiling under diet-controlled conditions demonstrated that the HFD component was responsible for this effect. The esophageal microbiota in humans is thought to be transitory, and may change in association with esophagitis<sup>51</sup>, whereas the microbiota of the lower GI tract is quantitatively much greater, with potential systemically mediated inflammatory effects. Indeed, the “pathogenic microbial community” theory suggests that the entire microbial community contributes to pathogenicity, even though no individual community members can be clearly categorized as causative pathogens<sup>52</sup>. We noted a correlation between TLR signaling in GSEA and upregulation of TLR2 in the esophagus, linking the alteration of the gut microbiota to IL8 signaling. In terms of a preventive antibiotic treatment for patients with BE the knowledge of distinct components of the microbiome seems essential, as too long term antibiotic treatment seems to be a difficult option and broad short term antibiotic treatment will result in a fast reconstitution of commensal bacteria<sup>53</sup>.

In summary (Suppl. Fig. 9), we propose here that a diet enriched in fat, rather than increased body weight, is responsible for accelerated esophageal carcinogenesis. While IL-1B-dependent chronic inflammation on its own can cause dysplasia, HFD accelerates this disease phenotype by altering the intestinal microbiome and inducing a distinct inflammatory response in the esophagus marked by IL8/KC chemokines. Increased esophageal IL8 expression alters the neutrophils/NK cell ratio and promotes the expansion at Cxcr2+ progenitors that eventually progress to dysplasia. These findings offer some potential new strategies for prevention of BE and EAC and should be investigated further in patient cohorts.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Funding:

The research leading to these results has received funding from the Deutsche Forschungsgemeinschaft (DFG) under Grant Agreement No. SFB 824 and has been funded by the Deutsche Krebshilfe with in the Max Eder Program to MQ. Additionally, TCW (PI) and MQ were funded by the NCI Barrett's Esophageal Translational Research Network (2 U54 CA163004–06). JI, NSM, MQ, DH MK were funded by a graduate program by the German Research Fund (GRK 1482)

## Abbreviations:

<b>BE</b>	Barrett's esophagus
<b>EAC</b>	Esophageal adenocarcinoma
<b>GEJ</b>	Gastroesophageal junction
<b>GERD</b>	Gastro-esophageal reflux disease
<b>GF</b>	germfree
<b>HFD</b>	High fat diet
<b>NK cells</b>	Natural killer cells
<b>SCJ</b>	squamocolumnar junction
<b>WT</b>	Wildtype

## References

1. Quante M, Graham TA, Jansen M. Insights into the Pathophysiology of Esophageal Adenocarcinoma. *Gastroenterology* 2017.
2. di Pietro M, Alzoubaidi D, Fitzgerald RC. Barrett's esophagus and cancer risk: how research advances can impact clinical practice. *Gut Liver* 2014;8:356–70. [PubMed: 25071900]
3. Maret-Ouda J, El-Serag HB, Lagergren J. Opportunities for Preventing Esophageal Adenocarcinoma. *CancerPrevRes(Phila)* 2016;9:828–834.
4. El-Serag HB, Hashmi A, Garcia J, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. *Gut* 2014;63:220–9. [PubMed: 23408348]
5. Nguyen TH, Thrift AP, Ramsey D, et al. Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. *Am J Gastroenterol* 2014;109:1870–80. [PubMed: 25420546]
6. Goodwin PJ, Chlebowski RT. Obesity and Cancer: Insights for Clinicians. *J Clin Oncol* 2016;34:4197–4202. [PubMed: 27903158]
7. Thrift AP, Hilal J, El-Serag HB. Metabolic syndrome and the risk of Barrett's oesophagus in white males. *Aliment Pharmacol Ther* 2015;41:1182–9. [PubMed: 25801197]
8. Tabung FK, Liu L, Wang W, et al. Association of Dietary Inflammatory Potential With Colorectal Cancer Risk in Men and Women. *JAMA Oncol* 2018.
9. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014;505:559–63. [PubMed: 24336217]

10. Beyaz S, Mana MD, Roper J, et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. *Nature* 2016;531:53–8. [PubMed: 26935695]
11. Ericksen RE, Rose S, Westphalen CB, et al. Obesity accelerates *Helicobacter felis*-induced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response. *Gut* 2013.
12. Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013;11:1399–1412 e7. [PubMed: 23707461]
13. Schulz MD, Atay C, Heringer J, et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. *Nature* 2014;514:508–12. [PubMed: 25174708]
14. Quante M, Bhagat G, Abrams JA, et al. Bile Acid and Inflammation Activate Gastric Cardia Stem Cells in a Mouse Model of Barrett-Like Metaplasia. *Cancer Cell* 2012;21:36–51. [PubMed: 22264787]
15. Asfaha S, Dubeykovskiy AN, Tomita H, et al. Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. *Gastroenterology* 2013;144:155–66. [PubMed: 23041326]
16. Bolze F, Rink N, Brumm H, et al. Characterization of the melanocortin-4-receptor nonsense mutation W16X in vitro and in vivo. *Pharmacogenomics J* 2013;13:80–93. [PubMed: 21969101]
17. Lertpiriyapong K, Whary MT, Muthupalani S, et al. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the *Helicobacter pylori* INS-GAS mouse model of gastric carcinogenesis. *Gut* 2014;63:54–63. [PubMed: 23812323]
18. Farooqi IS, Yeo GS, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. *J Clin Invest* 2000;106:271–9. [PubMed: 10903343]
19. Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. *Gut* 2002;51:316–22. [PubMed: 12171950]
20. Catusse J, Liotard A, Loillier B, et al. Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2. *Biochem Pharmacol* 2003;65:813–21. [PubMed: 12628493]
21. Spiegel A, Brooks MW, Houshyar S, et al. Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. *Cancer Discov* 2016;6:630–49. [PubMed: 27072748]
22. Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. *Cell* 2011;145:1023–35. [PubMed: 21703447]
23. Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, et al. Integrated genomic characterization of oesophageal carcinoma. *Nature* 2017;541:169–175. [PubMed: 28052061]
24. O'Neil A, Petersen CP, Choi E, et al. Unique Cellular Lineage Composition of the First Gland of the Mouse Gastric Corpus. *J Histochem Cytochem* 2017;65:47–58. [PubMed: 27872404]
25. Elliott DR, Walker AW, O'Donovan M, et al. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. *Lancet Gastroenterol Hepatol* 2017;2:32–42. [PubMed: 28404012]
26. Kubeck R, Bonet-Ripoll C, Hoffmann C, et al. Dietary fat and gut microbiota interactions determine diet-induced obesity in mice. *Mol Metab* 2016;5:1162–1174. [PubMed: 27900259]
27. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 2013;31:814–21. [PubMed: 23975157]
28. Abrams JA, Sharaiha RZ, Gonsalves L, et al. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940–2007. *Cancer Epidemiol Biomarkers Prev* 2011;20:183–6. [PubMed: 21127287]
29. Rieder F, Bianchini P, Harnett K, et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. *American Physiological Society* 2010;298:G571–G581.



30. Hardikar S, Onstad L, Song X, et al. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort. *Cancer Epidemiol Biomarkers Prev* 2014.
31. Xing F, Saidou J, Watade K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. *Front Biosci.* 2011;15:166–179.
32. Shrivastava MS, Hussain Z, Giricz O, et al. Targeting chemokine pathways in esophageal adenocarcinoma. *Cell Cycle* 2014;13:3320–7. [PubMed: 25485576]
33. Cook MB, Barnett MJ, Bock CH, et al. Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium. *Gut* 2018.
34. Garcia JM, Splenser AE, Kramer J, et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. *Clin Gastroenterol Hepatol* 2014;12:229–238 e3. [PubMed: 23954649]
35. Thrift AP, Garcia JM, El-Serag HB. A multibiomarker risk score helps predict risk for Barrett's esophagus. *Clin Gastroenterol Hepatol* 2014;12:1267–71. [PubMed: 24362047]
36. Bhattacharyya S, Borthakur A, Pant N, et al. Bcl10 mediates LPS-induced activation of NF-kappaB and IL-8 in human intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 2007;293:G429–37. [PubMed: 17540779]
37. Adler BJ, Green DE, Pagnotti GM, et al. High fat diet rapidly suppresses B lymphopoiesis by disrupting the supportive capacity of the bone marrow niche. *PLoS One* 2014;9:e90639. [PubMed: 24595332]
38. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. *Nat Rev Cancer* 2016;16:431–46. [PubMed: 27282249]
39. Waight JD, Hu Q, Miller A, et al. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. *PLoS One* 2011;6:e27690. [PubMed: 22110722]
40. Casbon A-J, Reynaud D, Park C, et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. *Proc Natl Acad Sci USA* 2015;112:E566–575. [PubMed: 25624500]
41. Xu B, Chen L, Li J, et al. Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients. *Oncotarget* 2016;7:74904–74916. [PubMed: 27736796]
42. Quail DF, Olson OC, Bhardwaj P, et al. Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF. *Nat Cell Biol* 2017;19:974–987. [PubMed: 28737771]
43. Alexeev V, Salas-Alanis JC, Palisson F, et al. Pro-inflammatory chemokines and cytokines dominate the blister fluid molecular signature in epidermolysis bullosa patients and affect leukocyte and stem cell migration. *J Invest Dermatol* 2017.
44. Ray K High-fat diet influences intestinal stem cell biology. *Nature Reviews Gastroenterology & Hepatology* 2016;13:250–251.
45. Duggan C, Onstad L, Hardikar S, et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. *Clin Gastroenterol Hepatol* 2013;11:934–43. [PubMed: 23466711]
46. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science* 2011;334:105–8. [PubMed: 21885731]
47. Kim HJ, Li H, Collins JJ, et al. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. *Proc Natl Acad Sci USA* 2016;113:E7–15. [PubMed: 26668389]
48. Schueller K, Riva A, Pfeiffer S, et al. Members of the Oral Microbiota Are Associated with IL-8 Release by Gingival Epithelial Cells in Healthy Individuals. *Front Microbiol* 2017;8:416. [PubMed: 28360899]
49. Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. *Nat Med* 2018;24:1919–1929. [PubMed: 30397356]
50. Snider EJ, Compres G, Freedberg DE, et al. Barrett's esophagus is associated with a distinct oral microbiome. *Clin Transl Gastroenterol* 2018;9:135. [PubMed: 29491399]

51. Yang L, Lu X, Nossa CW, et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. *Gastroenterology* 2009;137:588–97. [PubMed: 19394334]
52. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: Human gut microbes associated with obesity. *Nature* 2006;444:1022–1023. [PubMed: 17183309]
53. Weber D, Hiergeist A, Weber M, et al. Detrimental effect of broad-spectrum antibiotics on intestinal microbiome diversity in patients after allogeneic stem cell transplantation: Lack of commensal sparing antibiotics. *Clin Infect Dis* 2018.

**Need to Know****Background:**


We investigated whether a high-fat diet and/or obesity contribute to progression of Barrett's esophagus (BE) to esophageal cancer in a mouse model and by studying esophageal tissues from patients with BE.

**Findings:**

We found a high-fat diet to promote esophageal dysplasia by altering the intestinal microbiome and promoting inflammation and stem cell expansion, independent of obesity.

**Implications for Patient Care:**

Patients with BE should be encouraged to avoid a high-fat diet.



**Figure 1. HFD accelerates esophageal dysplasia in the L2-IL1B mouse model.**

(A) (i) macroscopic image and representative pictures of (ii) Haematoxylin & Eosin (H&E), (iii) Periodic acid–Schiff (PAS) and (iv) Ki67 of the SCJ. A WT Chow mouse was used as a representative for all WT mice. Macroscopic tumor score at 3–12 months (mean  $\pm$  SEM) (B), inflammation (C) metaplasia (D), and dysplasia scores (E) (n=8–12, mean  $\pm$  SD). Quantification of (F) PAS and (G) Ki67 staining (n=8–12). (H) Body weight of L2-IL1B mice. (I) Correlations between body mass and dysplasia score. Quantification of 4 high-magnification-field (20X) of esophagus and SCJ tissue (\*\*\*\*p<0.0001, \*\*\*p<0.001, \*\*p<0.01, \*p<0.05) For (B–E) 2-way ANOVA with Sidak-Holm post-hoc was used, for

(F,G) a 1 way ANOVA with Tukey post-hoc and for (H,I) 2 way ANOVA with Tukey Post-hoc. BE region was defined as the region between squamous epithelium and oxyntic mucosa of the stomach. L2=L2-IL-1 $\beta$ , WT=wildtype, HFD=High fat diet


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





**Figure 2. HFD induces a systemic immune response leading to a distinct local inflammatory microenvironment reaction**

(A) Gene expression analysis from SCJ tissue (n=3). (B) Cytokine array for chemoattractants of immune cells and cytokines/chemokines related to immune cell differentiation, cell survival, proliferation, angiogenesis and apoptosis in pooled esophageal tissue from 12 month old L2-IL1 $\beta$  mice on Chow (n=4) or HFD (n=6). (C) Treatment with serum from L2-IL1 $\beta$  mice on HFD induces proliferation of 3D mouse BE organoids from L2-IL1 $\beta$  mice (Serum was collected and pooled from L2-IL1 $\beta$  mice maintained on Chow or HFD (n=3)). (D) qRT-PCR of CXCL1/KC in SCJ of L2-IL1 $\beta$  mice on HFD at 12 months (n=6). (E) a-SMA<sup>+</sup> staining in L2-IL1 $\beta$  mice on HFD (n=6). (F) IL8 concentration in supernatant from esophageal squamous (Het), BE (QH) and EAC cell lines OE33 (n=3). (G) IL8 concentration in tissue conditioned medium from human normal esophagus, oesophagitis, BE and EAC. (n=10). NCM-normal conditioned medium, OCM-oesophagitis, BCM-BE, and TCM-EAC. Data are represented as mean  $\pm$  SEM (\*\*\*p<0.0001, \*\*\*p<0.001, \*\*p<0.01, \*p<0.05) For (C,D) 2 way ANOVA with Sidak-Holm post-hoc was




used, for (E,F) 1 way Anova with Tukey post-hoc was used. (G) used a Kruskal-Wallis test against NCM and Dunns post-ho. L2=L2-IL-1 $\beta$ , WT=wildtype, HFD=High fat diet

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript



**Figure 3. IL8 is one of the key cytokines that accelerates esophageal dysplasia in HFD mice.** (A) Representative macroscopic pictures and Haematoxylin & Eosin (H&E) staining and (B) macroscopic tumor score in L2-IL1B/IL8Tg mice (n=10). (C) metaplasia and (D) dysplasia score in mice (n=8, mean ± SD). (E) Ki67 (F) PAS and (G) a-SMA<sup>+</sup> staining in L2-IL1B/IL8Tg mice (n=6, mean ± SEM). (H) Gene Set Enrichment Analysis (GSEA): Differential expression between (i) WT HFD and Chow mice, (ii) L2-IL1B and WT Chow mice and (iii) L2-IL1B HFD and Chow mice (n=3) and analyzed with IL8 gene set, generated by utilizing gene expression data from L2-IL1B/IL8Tg mice and L2-IL-1β mice (n=3, mean ± SEM). (I) 3D mouse BE organoids from L2-IL1B/IL8Tg mice co-cultured with human lean or obese serum (pooled from 10 patients) for 48 hours. (\*\*\*\*p<0.0001, \*\*\*p<0.001, \*\*p<0.01, \*p<0.05) For (B-D) a 2 way Anova with Sidak-Holm post-hoc was used. (E-G) use a 1 way Anova with Tukey post-hoc. (I) uses a t-test. L2=L2-IL-1β, L2/IL8Tg=L2-IL-1β/IL8Tg, HFD=High fat diet.



**Figure 4. HFD induces a specific immune response with neutrophils infiltration and NK cells reduction.**

(A) FACS of neutrophils, immature myeloid cells (IMC) and NK cells in the esophagus of HFD mice at 12 months (n=9-11). (B) IHC of neutrophils (Ly6G), immature myeloid cells (Ly6C) and macrophages (F4/80) in the squamous epithelium in 10 low power fields (n=3). (C) FACS of neutrophils in esophagus of L2-IL1 $\beta$ /IL8Tg mice (n=5-8). (D) IHC of neutrophils (Ly6G) in L2-IL1 $\beta$ /IL8Tg mice (n=3). (E) Cxcr2 expression and (F) score in the esophagus of L2-IL1 $\beta$  mice on HFD and in L2-IL1 $\beta$ /IL8Tg mice (n=8). (G) Proliferation of BE organoids of L2-IL1 $\beta$  mice co-cultured with neutrophils from the spleens of 9-12

months old L2-IL-1  $\beta$  mice including a representative image of the organoids (n=3). (H) and (I) Cytokine arrays of BE organoid co-culture with neutrophils. Data are represented as mean  $\pm$  SEM (\*p<0.05) (A-C) use t-tests. (D,F) uses a 1 way Anova with Tukey post-hoc. (G) is a repeated measure 2 way Anova with Tukey post-hoc. L2=L2-IL-1 $\beta$ , L2/IL8Tg=L2-IL-1 $\beta$ /IL8Tg, HFD=High fat diet.


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





**Figure 5. The esophageal inflammatory niche recruits SCJ progenitor cells**

(A) CXCR2 expression in BE in L2-IL1B mice on HFD and in L2-IL1B/IL8Tg mice and germfree L2-IL1B mice (n=4–8). GSEAs for (B) a mouse epithelial (cancer) stem cells gene signatures comparing L2-IL1B HFD vs. L2-IL1B Chow and L2-IL1B/IL8Tg vs. L2-IL1B Chow or a (C) human migratory cancer cell gene signature. (D) ISH for Lgr5<sup>+</sup> progenitor cells at the SCJ in the BE region in L2-IL-1B mice on HFD and in L2-IL1B/IL8Tg mice compared to germfree L2-IL1B mice (n=5–7). (E) ISH show co-expression of Lgr5<sup>+</sup> (brown) and CXCR2 (red) progenitor cells. (F) Crypt fission in L2-IL1B HFD mice and L2-

IL1B/IL8Tg mice. Data are represented as mean  $\pm$  SEM (\*p<0.05). L2=L2-IL-1 $\beta$ , L2/IL8Tg=L2-IL-1 $\beta$ /IL8Tg, HFD=High fat diet.


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





**Figure 6. The effect of HFD on the intestinal microbiome.**

(A) Weighted Unifrac plot shows  $\beta$ -diversity after 16S-rRNA gene-sequencing of feces from L2-IL1B and WT mice on Chow (n=10), Control (n=6) and HFD (n=10) at the age of 6 months. (B) Ratio of the phylum Firmicutes to Bacteroidetes calculated after 16S-rRNA sequencing. Left: WT and L2-IL1B mice. Right: patient cytosponge samples (Control n=20, BE n=24, HGD n=23). (C) Representative H&E staining of SCJ and (D) Quantification of inflammation, metaplasia, dysplasia scores and goblet cell ratio in germfree (n=8, age 14 months, mean  $\pm$  SD) and conventional L2-IL1B mice (n=16, age 11.5–16.5 months). (E) Representative pictures and quantification of IHC of neutrophils in the squamous epithelium

in 10 low power fields (Ly6G) and IMCs (Ly6C) in germfree L2-IL1B mice (Germfree n=8, L2-IL1B-Chow n=3, L2-IL1B-HFD n=4). Groups with grey background are same mice as in Figure 4B. (F) Dysplasia score of L2-IL1B mice on control diet exposed to the old bedding of HFD L2-IL-1 $\beta$  mice (G) Principal component analysis of all significantly regulated KEGG pathways of the microbiome of WT (left) and L2-IL1B mice (right) at 6 months. (H) KEGG pathways of the microbiome in WT vs L2-IL1B mice on Chow (n=10 each), Control (n=6 each) and HFD (n=10 each) predicting the microbiomes function with PICRUSt. (I) KEGG pathway prediction of LPS synthesis. (J and K) GSEAs show an enrichment of mouse derived LPS response and TLR signaling in L2-IL1B-HFD mice. Data are represented as mean  $\pm$  SEM. \*p<0.05, \*\*p<0.01 \*\*\*p<0.001. (B,E,F) used a 1-way ANOVA with Tukey post-hoc testing. For (D) a t-test was used. L2=L2-IL-1 $\beta$ , wt=wildtype, HFD=High fat diet.